All In Biotech

Company

Servier

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

3

3 still marketed

Novel approvals

3

Approvals since 2021

4

Originals and new uses

Phase 3 trials

24

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Voranigo approved NovelBreakthrough therapyPriority reviewOrphanAug 6, 2024
  • Tibsovo new use Breakthrough therapyPriority reviewOrphanOct 24, 2023
  • Tibsovo new use Breakthrough therapyPriority reviewOrphanMay 25, 2022
  • Tibsovo new use Priority reviewOrphanAug 25, 2021
  • Tibsovo new use Priority reviewMay 2, 2019
  • Asparlas approved NovelOrphanDec 20, 2018
  • Tibsovo approved NovelPriority reviewOrphanJul 20, 2018

Drugs in development (2)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • S241656Phase 21 trial

    Servier · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia

  • S243249Phase 21 trial

    Servier · Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia

Recruiting Phase 3 trials

Largest first.

Marketed drugs (3)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.